Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Failure Of J&J/Conor’s CoStar Stent Trial Sets Program Back Up To Four Years

This article was originally published in The Gray Sheet

Executive Summary

Johnson & Johnson's Conor Medsystems unit will discontinue development of its CoStar paclitaxel-eluting coronary stent and terminate sales of the device overseas following the failure of the firm's CoStar II U.S. pivotal study
Advertisement

Related Content

And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market
And Then There Were Three: J&J/Cordis Exits Drug-Eluting Stent Market
Angiotech and Conor settle
Angiotech and Conor settle
Cordis Consolidation Will Help J&J Save $1.6 Billion In 2008
Cordis-Medinol stent deal
J&J Medical Device Revenue Up, But Cypher Sales Are Still A Drag
Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC
J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
Advertisement
UsernamePublicRestriction

Register

MT024788

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel